# Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

> **NCT05815290** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 50 (estimated)

## Conditions studied

- dMMR Colorectal Cancer

## Interventions

- **DRUG:** Cadonilimab

## Key facts

- **NCT ID:** NCT05815290
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-29
- **Primary completion:** 2024-09-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05815290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05815290, "Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05815290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*